Tag: Bayer

Bayer shares experienced a decline on Wednesday, despite the company announcing a significant advancement in its Parkinson's disease treatment program. ...

Bayer's subsidiary AskBio has initiated a European Phase II clinical trial for its innovative gene therapy candidate, AB-1005, targeting Parkinson's ...

Bayer AG faces renewed pressure as a highly anticipated cardiovascular drug candidate failed to meet its primary endpoint in critical ...

Bayer's pharmaceutical division has encountered a significant clinical development hurdle as its promising heart failure drug candidate, Vericiguat, failed to ...

Bayer's stock finds itself trapped between opposing forces, unable to achieve any meaningful momentum. While the company's core operations continue ...

A recent assessment from Fitch Ratings has presented Bayer investors with a complex picture. The agency's decision to affirm the ...

Bayer's latest quarterly results have left investors divided, as a surprise €2.1 billion adjusted operating profit—boosted by a €150 million ...

The pharmaceutical and agrochemical giant has intensified its restructuring, slashing 12,000 full-time jobs—nearly double the figure announced earlier this year. ...